Immunai Inc., a leading artificial intelligence (AI) biotech company specializing in mapping the human immune system, today announced the appointment of Mikael Dolsten, M.D., Ph.D., to its Board of Directors. Dr. Dolsten, who served most recently as Pfizer’s Chief Scientific Officer and President of Research & Development for 15 years, brings decades of experience leading drug and vaccine discovery and development. He will support Immunai’s mission to integrate AI into immunology and oncology research, helping drive precise and efficient therapeutic innovation.

During his tenure at Pfizer, Dr. Dolsten led a team of thousands of scientists, overseeing research across all therapeutic areas. His leadership resulted in the approval of more than 35 new drugs and vaccines, including the first mRNA-based COVID-19 vaccine. His work has contributed to treatments for rheumatoid arthritis, stroke prevention, cancer, and several vaccines.

“Pharma continues turning to AI to better understand diseases and speed up drug discovery and development,” said Noam Solomon, Ph.D., CEO and Co-Founder of Immunai. “But moving from data to real treatments takes deep expertise. Mikael has spent decades leading drug development at the highest level, and his experience will help us apply AI in ways that drive real progress in drug development.”

Before joining Pfizer in 2009, Dolsten held senior leadership roles at Wyeth, Boehringer Ingelheim, and AstraZeneca, where he led global R&D efforts and contributed to drug discovery across multiple therapeutic areas. Throughout his career, he has helped select some 200 drug candidates and advanced up to 50 new regulatory approvals. 

“Immunai’s AI model of the immune system is reshaping how we approach therapeutic discovery and development,” said Mikael Dolsten, M.D., Ph.D. “Having previously collaborated with Immunai, I’ve seen first-hand how their AI and immunomics capabilities can enhance drug development efficiency and success rates. By leveraging AI to analyze immune responses at single-cell resolution, we can accelerate the development of innovative treatments and bring them to patients faster. I’m excited to continue to be part of Immunai’s journey in transforming drug discovery and development through a deep understanding of the immune system.”

Dr. Dolsten’s appointment comes on the heels of Immunai’s pivotal multi-year collaborations with AstraZeneca and Teva Pharmaceuticals, both of which underscore the growing importance of AI-driven insights in clinical development. These partnerships leverage Immunai’s proprietary immune cell atlas, AMICA™, and Immunodynamics Engine (IDE)™ to address critical challenges in drug development—ranging from dose selection and biomarker discovery to understanding mechanisms of action and predicting patient responses. 

For more information about Immunai, please visit www.immunai.com.